文献速递基层心理健康慢病管理

拉莫三嗪与锂盐在基层精神科会诊中的采纳与不良反应

Lamotrigine and lithium in primary care psychiatric consultation: adoption and adverse effects.
PubMed 文献 · Fam Pract · 2021-01-01

本研究回顾性分析协作医疗模式中620例抑郁成人患者(PHQ-9≥10)的病历,精神科会诊医生推荐拉莫三嗪和锂盐的比例分别为35%和26%,基层医生实际处方率分别为50%和32%;锂盐组12%患者TSH超过正常上限,平均出现在初始处方后32天,且体重增加不高于拉莫三嗪组。

要点

  • 协作医疗会诊中拉莫三嗪和锂盐推荐频率高,但基层实际处方采纳率仅约50%和32%。
  • 低剂量锂盐仍可快速引起TSH升高,12%患者超过正常上限,平均32天出现。

核心结论

  • 在协作医疗精神科会诊项目中,拉莫三嗪和锂盐的推荐非常频繁,但采纳情况不一,值得进一步研究。
  • 低剂量锂盐与较高剂量一样可快速诱发甲状腺功能减退,但不引起体重增加。

研究设计与样本

  • 采用病历回顾方法,纳入620例抑郁成人患者(PHQ-9≥10),分析精神科会诊医生对拉莫三嗪和锂盐的推荐频率、基层医生处方采纳率及不良反应。

主要发现

  • 精神科会诊医生推荐拉莫三嗪和锂盐的比例分别为35%和26%。
  • 推荐后基层医生实际处方拉莫三嗪和锂盐的比例分别为50%和32%。
  • 随访至6个月,锂盐组体重增加不高于拉莫三嗪组。
  • 12%接受锂盐治疗的患者TSH超过正常上限,平均出现在初始处方后32天。

临床怎么用

  • 在协作医疗模式下,基层医生可依据精神科会诊建议考虑对双相抑郁使用拉莫三嗪或锂盐。
  • 使用锂盐时,即使低剂量也应早期(如约1个月内)监测TSH,警惕甲状腺功能减退。

局限性

  • 本研究为病历回顾性分析,未报告随机化或盲法,可能存在选择偏倚。
  • 研究未评估上述药物治疗对抑郁结局的改善效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Collaborative Care Model of psychiatric consultation in primary care has improved outcomes for unipolar depression, but bipolar depressions are challenging for providers and consultants. Although lamotrigine and lithium are both first line medications for bipolar depression, their use in primary care has been declining over the last decade. OBJECTIVE: Our project aimed to quantify the frequency of and adoption of recommendations for lamotrigine and lithium, and their adverse effects, in a Collaborative Care program. METHODS: Chart review. RESULTS: For 620 depressed adult patients (Public Health Questionnaire, 9-item ≥10), lamotrigine and lithium were recommended by psychiatric consultant for 35% and 26% of patients, respectively; and when recommended, were prescribed by primary care providers 50% and 32% of the time, respectively. Eighty-four percent of lithium dosages were 600 mg or less; average serum level 0.32 mEq/l. In follow-up up to 6 months, lithium was associated with no more weight gain than lamotrigine; but 12% of patients receiving lithium had thyroid stimulating hormone increases exceeding the upper limit of normal, occurring in an average of 32 days after the initial prescription. CONCLUSIONS: (i) In a Collaborative Care program of psychiatric consultation, recommendations for lamotrigine and lithium were very frequent. (ii) Adoption of these recommendations is variable, warranting further investigation. (iii) Like higher doses, low doses of lithium induced hypothyroidism (rapidly)-but not weight gain. Depression is a common problem. One variation, bipolar depression, often does not respond well to antidepressants. But bipolar depression is hard to diagnose, especially in busy primary care clinics. With too few psychiatrists available, primary care providers have often had to treat bipolar depression themselves. To address this problem, in the USA a system of consultation (‘Collaborative Care’) has been developed that allows a remote psychiatrist to make treatment recommendations for patients based on data gathered by the primary care team. In this study of 620 patients with depression, we looked at how often psychiatric consultants recommended two medications for bipolar depression which tend to be underused: lamotrigine and lithium. We found that lamotrigine was recommended for one third of these 620 patients, and lithium for one quarter—much higher percentages than are routine in primary care of depression. But because either the providers or their patients were hesitant about these medications, actual prescriptions were fewer: 50% of the times when it was recommended for lamotrigine; 32% for lithium. Side effects were few. This study shows that psychiatric consultation leads to increased use of important medications for bipolar depression. Now we need a study to show it helps improve outcomes!

来源:Fam Pract,查看原文。版权归原作者所有。

引用

  1. Phelps JR, Pipitone OR, Squires K, et al. Lamotrigine and lithium in primary care psychiatric consultation: adoption and adverse effects. Fam Pract. 2021. PMID: 33367908. doi:10.1093/fampra/cmaa131

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。